Alzinova AB (publ) (ALZ.ST)
SEK 1.93
(3.43%)
SEK 1.93
(3.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -21.22 Million SEK | 32.05% |
| 2022 | -31.23 Million SEK | -11.42% |
| 2021 | -28.03 Million SEK | 49.19% |
| 2020 | -55.17 Million SEK | -67.54% |
| 2019 | -32.93 Million SEK | 20.74% |
| 2018 | -41.55 Million SEK | -143.26% |
| 2017 | -17.08 Million SEK | 29.53% |
| 2016 | -24.24 Million SEK | -36.76% |
| 2015 | -17.72 Million SEK | -12915.41% |
| 2014 | 138.3 Thousand SEK | -56.41% |
| 2013 | 317.28 Thousand SEK | 254.7% |
| 2012 | -205.09 Thousand SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -12.2 Million SEK | 42.49% |
| 2024 Q2 | -4.18 Million SEK | 65.7% |
| 2023 Q2 | -35.78 Million SEK | -63.47% |
| 2023 Q3 | -32.1 Million SEK | 10.27% |
| 2023 Q4 | -21.22 Million SEK | 33.89% |
| 2023 FY | -21.22 Million SEK | 32.05% |
| 2023 Q1 | -21.88 Million SEK | 29.93% |
| 2022 FY | -31.23 Million SEK | -11.42% |
| 2022 Q4 | -31.23 Million SEK | 17.96% |
| 2022 Q1 | -25.97 Million SEK | 7.34% |
| 2022 Q2 | -43.26 Million SEK | -66.54% |
| 2022 Q3 | -38.07 Million SEK | 11.98% |
| 2021 FY | -28.03 Million SEK | 49.19% |
| 2021 Q3 | -33.54 Million SEK | 16.79% |
| 2021 Q2 | -40.3 Million SEK | 17.11% |
| 2021 Q4 | -28.03 Million SEK | 16.41% |
| 2021 Q1 | -48.62 Million SEK | 11.87% |
| 2020 Q3 | -15.46 Million SEK | 26.5% |
| 2020 Q4 | -55.17 Million SEK | -256.74% |
| 2020 FY | -55.17 Million SEK | -67.54% |
| 2020 Q1 | -25.53 Million SEK | 22.46% |
| 2020 Q2 | -21.04 Million SEK | 17.6% |
| 2019 Q3 | -35.91 Million SEK | 6.29% |
| 2019 Q1 | -39.84 Million SEK | 4.1% |
| 2019 FY | -32.93 Million SEK | 20.74% |
| 2019 Q4 | -32.93 Million SEK | 8.31% |
| 2019 Q2 | -38.32 Million SEK | 3.82% |
| 2018 Q3 | -7.8 Million SEK | 23.62% |
| 2018 FY | -41.55 Million SEK | -143.26% |
| 2018 Q2 | -10.21 Million SEK | 23.67% |
| 2018 Q1 | -13.37 Million SEK | 21.68% |
| 2018 Q4 | -41.55 Million SEK | -432.72% |
| 2017 Q1 | -22.86 Million SEK | 5.67% |
| 2017 FY | -17.08 Million SEK | 29.53% |
| 2017 Q4 | -17.08 Million SEK | 16.91% |
| 2017 Q3 | -20.55 Million SEK | 4.73% |
| 2017 Q2 | -21.58 Million SEK | 5.62% |
| 2016 FY | -24.24 Million SEK | -36.76% |
| 2016 Q3 | -13.05 Million SEK | 9.27% |
| 2016 Q2 | -14.38 Million SEK | 13.33% |
| 2016 Q1 | -16.6 Million SEK | 6.33% |
| 2016 Q4 | -24.24 Million SEK | -85.68% |
| 2015 Q1 | 261.69 Thousand SEK | 89.21% |
| 2015 FY | -17.72 Million SEK | -12915.41% |
| 2015 Q4 | -17.72 Million SEK | 0.0% |
| 2014 FY | 138.3 Thousand SEK | -56.41% |
| 2014 Q4 | 138.3 Thousand SEK | 0.0% |
| 2013 FY | 317.28 Thousand SEK | 254.7% |
| 2012 FY | -205.09 Thousand SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Amniotics AB (publ) | -5.63 Million SEK | -276.882% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -882.23% |
| BioArctic AB (publ) | -606.58 Million SEK | 96.501% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 493.074% |
| Genovis AB (publ.) | -43.94 Million SEK | 51.694% |
| LIDDS AB (publ) | -13.51 Million SEK | -57.09% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 139.881% |
| OncoZenge AB (publ) | -12.62 Million SEK | -68.1% |
| Saniona AB (publ) | 40.44 Million SEK | 152.479% |
| Simris Alg AB (publ) | 85.07 Million SEK | 124.95% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 93.638% |
| AcouSort AB (publ) | -23.98 Million SEK | 11.507% |
| Active Biotech AB (publ) | -33.2 Million SEK | 36.066% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.179% |
| Cantargia AB (publ) | -139.74 Million SEK | 84.811% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -2199.675% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 74.653% |
| Mendus AB (publ) | -96.29 Million SEK | 77.957% |
| Kancera AB (publ) | -45.69 Million SEK | 53.545% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 74.178% |
| Lipum AB (publ) | -8.46 Million SEK | -150.75% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 33.517% |
| NextCell Pharma AB | -46.79 Million SEK | 54.636% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 112.781% |
| Xintela AB (publ) | -7.8 Million SEK | -171.815% |
| Ziccum AB (publ) | -2.13 Million SEK | -893.262% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 27.761% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -11.364% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 84.635% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 83.609% |
| CombiGene AB (publ) | -101.44 Million SEK | 79.075% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 74.142% |
| Intervacc AB (publ) | -88.16 Million SEK | 75.923% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 57.566% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 57.492% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 203.491% |
| Corline Biomedical AB | -17.01 Million SEK | -24.771% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 74.653% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 46.102% |
| Aptahem AB (publ) | 2.9 Million SEK | 829.756% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 93.55% |
| Fluicell AB (publ) | -2.76 Million SEK | -668.223% |
| Biovica International AB (publ) | -58.73 Million SEK | 63.863% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 53.057% |
| Abliva AB (publ) | -57.24 Million SEK | 62.918% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 89.098% |
| 2cureX AB (publ) | -13.4 Million SEK | -58.368% |
| I-Tech AB | -83.26 Million SEK | 74.507% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 115.757% |
| Cyxone AB (publ) | -16.67 Million SEK | -27.331% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 62.019% |
| Biosergen AB | -1.88 Million SEK | -1027.244% |
| Nanologica AB (publ) | -9.38 Million SEK | -126.097% |
| SynAct Pharma AB | -61.75 Million SEK | 65.63% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 0.883% |
| BioInvent International AB (publ) | -236.3 Million SEK | 91.018% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -60.448% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 68.282% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -309.696% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -2.082% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -614.199% |